Package | us.nlm.vsac |
Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1078.932 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1078.932/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.932 |
Version | 20240709 |
Status | active |
Date | 2024-07-09T01:07:16-04:00 |
Name | SemaglutideSCMeds |
Title | Semaglutide SC meds |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: Medications containing subcutaneous semaglutide, including combination medications and medications with indications other than type 2 diabetes mellitus.),(Data Element Scope: RxCUIs at product level (SCD, GPCK, SBD, BPCK)),(Inclusion Criteria: Valid, prescribable RxCUIs (including retried RxCUIs) with subcutaneous semaglutide as ingredient),(Exclusion Criteria: Invalidated RxCUIs and oral forms) |
ValueSet | |
2.16.840.1.113762.1.4.1078.933 | T2DM meds benefitting ASCVD |
2.16.840.1.113762.1.4.1078.934 | T2DM meds benefitting CKD stages 2, 3, and 4 with eGFR >= 20 mL/min |
2.16.840.1.113762.1.4.1078.935 | T2DM meds benefitting CKD stage 5 |
CodeSystem | |
rxnorm | RxNorm |
rxnorm | RxNorm |
No narrative content found in resource